Publications by authors named "Zhan-Ming Shi"
Background: Intravenous (IV) ketamine has been evaluated alongside electroconvulsive therapy (ECT) in addressing major depressive disorder (MDD) or bipolar depression (BD), though the comparative outcomes remain inconclusive. This meta-analysis aimed to provide a systematic assessment of the efficacy, safety, and tolerability of IV ketamine relative to ECT for treating MDD or BD.
Methods: Randomized controlled trials (RCTs) comparing IV ketamine and ECT in terms of efficacy, safety, and tolerability for MDD or BD were identified and reviewed.
Article Synopsis
- - The study reviewed the effectiveness and safety of deep transcranial magnetic stimulation (dTMS) for treating schizophrenia, finding it does not significantly reduce psychotic symptoms compared to sham treatment.
- - Three randomized clinical trials (RCTs) with 80 patients were analyzed, revealing that while dTMS didn’t improve overall psychopathology, it possibly enhanced some aspects of executive function.
- - The review indicated moderate dropout rates (16.7% to 44.4%) and some reported side effects, like tingling and discomfort, highlighting the need for more extensive RCTs to explore dTMS's impact on schizophrenia further.
Background: In randomized clinical trials (RCTs) investigating the application of transcranial alternating current stimulation (tACS) in schizophrenia, inconsistent results have been reported. The purpose of this exploratory systematic review of RCTs was to evaluate tACS as an adjunct treatment for patients with schizophrenia based on its therapeutic effects, tolerability, and safety.
Methods: Our analysis included RCTs that evaluated adjunctive tACS' effectiveness, tolerability, and safety in schizophrenia patients.
Objective: This meta-analysis of randomized clinical trials (RCTs) was conducted to explore the therapeutic effects, tolerability and safety of repetitive transcranial magnetic stimulation (rTMS) as an adjunct treatment in adolescents with first-episode major depressive disorder (FE-MDD).
Methods: RCTs examining the efficacy, tolerability and safety of adjunctive rTMS for adolescents with FE-MDD were included. Data were extracted by three independent authors and synthesized using RevMan 5.
Objective: This meta-analysis of randomized controlled trials (RCTs) evaluated the overall efficacy and safety of bilateral theta-burst stimulation (TBS) as an intervention for patients with mood disorders.
Methods: A systematic search (up to December 7, 2022) of RCTs was conducted to address the study aims. A random-effects meta-analysis was performed by including study-defined responses and remission as primary outcomes.
Article Synopsis
- Magnetic seizure therapy (MST) is a new treatment for depression that shows promise as an alternative to electroconvulsive therapy (ECT), with fewer cognitive side effects.
- A systematic review analyzed data from four randomized controlled trials (RCTs) to compare the efficacy and safety of MST and ECT, finding no significant differences in response, remission, or symptom improvement.
- Results indicated that while MST has a comparable antidepressant effect to ECT, there are mixed results regarding cognitive side effects, with limited data on adverse drug reactions.
Objective: This systematic review of randomized controlled trials (RCTs) was conducted to explore the therapeutic effects and safety of active low-frequency repetitive transcranial magnetic stimulation (LF-rTMS) versus sham LF-rTMS in children and adolescent patients with first-episode and drug-naïve (FEDN) major depressive disorder (MDD).
Methods: A systematic literature search was performed, and data were extracted by two independent researchers. The coprimary outcomes were study-defined response and remission.
The efficacy and safety of adjunctive nonconvulsive electrotherapy (NET) for patients with depression are undetermined. This systematic review was conducted to examine the efficacy and safety of adjunctive NET for patients with depression. Chinese (WanFang and Chinese Journal Net) and English (PubMed, EMBASE, PsycINFO and the Cochrane Library) databases were systematically searched from their inception until Jan 27, 2021 by three independent investigators.
View Article and Find Full Text PDFBackground: The use of ketamine in electroconvulsive therapy (ECT) has been examined in the treatment of major depressive disorder (MDD); however, there has been no systematic review and meta-analysis of related randomised controlled trials (RCTs).
Aim: To examine the efficacy and safety of ketamine augmentation of ECT in MDD treatment.
Methods: Two reviewers searched Chinese (China National Knowledge Infrastructure and Wanfang) and English (PubMed, PsycINFO, Embase and Cochrane Library) databases from their inception to 23 July 2019.
Background: Hyperprolactinaemia is a common antipsychotic (AP)-induced adverse effect, particularly in female patients.
Aims: This meta-analysis examined the efficacy and safety of adjunctive aripiprazole in preventing AP-related hyperprolactinaemia in patients with first-episode schizophrenia.
Methods: PubMed, PsycINFO, EMBASE, Cochrane Library, WanFang and China Journal Net databases were searched to identify eligible randomised controlled trials (RCTs).
Background: Results of previous studies on the safety and efficacy of adjunctive reboxetine for schizophrenia have been inconsistent.
Aim: The aim of this study was to examine the efficacy and tolerability of reboxetine as an adjunct medication to antipsychotic treatment in a meta-analysis of randomized controlled trials (RCTs).
Methods: Two independent investigators extracted data for a random effects meta-analysis and assessed the quality of studies using risk of bias and the Jadad scale.
Background: Hyperprolactinaemia is a common adverse effect of antipsychotics (APs). The results of Peony-Glycyrrhiza decoction (PGD) as a potentially useful adjunctive treatment for hyperprolactinaemia are inconsistent.
Aim: This meta-analysis of randomised controlled trials (RCTs) examined the efficacy and safety of adjunctive PGD therapy for AP-induced hyperprolactinaemia.